177Lu-FAP-2286

前言 放射性配体疗法（RLT）作为肿瘤靶向治疗领域的重要方向，其研发布局与临床进展备受关注。为全面梳理该领域的研发现状，研究截至 2025 年 3 月构建了涵盖69 种商业化临床开发阶段 RLT 的综合数据库，通过多源数据检索、人工交叉核验的严谨方式，系统收录了药物研发主体、放射性核素、靶向基团、作用靶点、肿瘤适应症及试验阶段等核心信息，剔除非符合判定标准的研究对象，确保数据的准确性与完整性。基于该全面且规范的数据库，展开肿瘤放射性配体疗法的研发布局分析，为行业了解 RLT 研发全貌、把握领域发展趋势提供详实参考。 原文 The landscape for radioligand therapies in oncology By Jerrick To, Rachel Magid, Jon Cleland, Val Panier & John Wu Nature Reviews Drug Discovery 24, 584-585 (2025) doi: https://doi.org/10.1038/d41573-025-00096-w 肿瘤放射性配体疗法的研发布局-数据库构建与分析 截至 2025 年 3 月，我们构建了包含69 种处于商业化临床开发阶段的放射性配体疗法（RLT）的综合数据库。 核心数据来源：本研究初始研究对象均从 EvaluatePharma 数据库中筛选得出。我们以“辐射”“放射性核素”“放射性药物” 为关键词，在 EvaluatePharma 总数据库的 “作用机制”“药理分类” 或 “治疗亚类” 字段中进行检索，筛选出相关研究对象。 验证过程：我们通过企业官网、企业报告及学术文献，对初步筛选得到的数据库进行人工交叉核验，以此对研究对象进行放射性配体疗法分类。不符合放射性配体疗法判定标准的放射性药物研究对象均被排除，排除标准包括：非全身给药、无明确的配体靶向基团（如 Xofigo / Ra-223、仅基于纳米颗粒或脂质体的制剂）、仅用于诊断目的。 开发阶段：已获批研究对象为目前已上市的药物；临床阶段研究对象为当前处于 I-Ⅲ期临床试验的药物，相关信息均来自企业官网和 / 或 ClinicalTrials.gov。对于联合无缝试验（如Ⅰ/Ⅱ 期或 Ⅰ/Ⅲ 期）中的研究对象，我们根据企业披露信息，或结合试验起止时间评估其当前研究节点，将其归至特定试验阶段；处于监管审评阶段的研究对象归为Ⅲ 期。 放射性核素：放射性配体疗法研究对象的放射性核素信息均来自企业官网及披露文件。我们根据核素衰变链中产生的更具创新性或临床价值的粒子类型，对放射性核素进行分类。图1中未纳入已在临床验证的前代放射性配体疗法及其他放射性药物中使用的核素（I- 123、I-131、Y- 90）；不同放射性核素对应的临床阶段放射性配体疗法详细分类情况见补充图 1。 靶向基团：靶向基团类型依据企业官网或公开文献中的明确分类确定；对于未明确标注靶向基团类型的研究对象，若其化学结构已知，则通过结构分析判定类型。肽类靶向基团依据具有明确结构的多个肽键和氨基酸序列识别，以此与非肽类小分子靶向基团区分。传统抗体指未经过特殊工程改造或修饰的抗体；工程化蛋白及抗体衍生物包括单重链抗体、单域抗体、抗原结合片段（Fabs）、纳米抗体、小蛋白、双特异性抗体及四聚体抗体。 作用靶点：放射性配体疗法研究对象的作用靶点信息均来自企业官网及披露文件。基于美国食品药品监督管理局（FDA）的获批信息，我们将靶点分为三类：放射性配体疗法验证靶点、其他疗法验证靶点（已有获批疗法针对该靶点）、探索性靶点（尚无任何获批疗法对其进行验证）。 肿瘤类型：各放射性配体疗法研究对象的靶向肿瘤类型信息来自企业官网和ClinicalTrials.gov。对于早期Ⅰ期研究对象，其靶向肿瘤类型通过查阅对应在研试验的入组标准进一步确定（注：多数Ⅰ期研究对象参与的是篮式试验，同时研究多种肿瘤类型）。若靶向肿瘤类型仅基于生物标志物确定（如SSTR2 +肿瘤、FAP+肿瘤），未明确具体肿瘤类型，则标注为“未指定”。在可行的情况下，将肿瘤类型归为更广泛的类别（如“黑色素瘤及皮肤肿瘤”包括黑色素瘤、默克尔细胞癌、葡萄膜黑色素瘤）。 新一代技术评估：我们将2000年代获批的放射性配体疗法定义为初代产品（Zevalin / 替伊莫单抗、Bexxar /托西莫单抗及I [131I]托西莫单抗）；近期获批并商业化的放射性配体疗法为现一代产品（Lutathera / Lu [177Lu]奥曲肽、Pluvicto/ Lu [177Lu]维泊妥肽）；临床阶段在研产品则归为新一代放射性配体疗法。我们通过查阅科学文献，评估不同技术的潜在应用价值及面临的挑战。 图 1 不同放射性核素对应的临床阶段放射性配体疗法 A.临床阶段放射性配体疗法中使用的放射性核素，按粒子发射类型及获批放射性药物中的临床验证情况分类（I-131、Y- 90、I-123 用于非靶向放射治疗或放射性诊断）。 B.临床阶段放射性配体疗法中主要新型放射性核素的发射粒子及衰变链。标注各放射性核素的半衰期（µs =微秒，ms =毫秒，s =秒，h =小时，d =天）。 表 1 商业化临床阶段的放射性配体疗法 企业 研究对象 放射性核素 靶向基团 作用靶点 肿瘤类型 试验阶段 Abdera Therapeutics ABD-147 Ac - 225 工程化抗体 / 蛋白 DLL3 肺神经内分泌肿瘤 Ⅰ期 Actinium Iomab-B I - 131 传统抗体 CD45 骨髓清髓 Ⅲ期 Actinium Actimab-A Ac - 225 传统抗体 CD33 急性髓系白血病 Ⅱ期 AdvanCell ADVC001 Pb - 212 非肽类小分子 PSMA 前列腺癌 Ⅰ期 Akysis AKY-1189 Ac - 225 工程化抗体 / 蛋白 Nectin-4 膀胱癌、乳腺癌、非小细胞肺癌、结直肠癌、宫颈癌 Ⅰ期 Ariceum SS0110（Lu-177） Lu - 177 肽类 SSTR2 肺神经内分泌肿瘤 Ⅰ期 Ariceum SS0110（Ac-225） Ac - 225 肽类 SSTR2 肺神经内分泌肿瘤、黑色素瘤及皮肤肿瘤 Ⅰ期 Ariceum ATT001 I - 123 非肽类小分子 PARPi 胶质母细胞瘤 Ⅰ期 ArtBio AB001 Pb - 212 非肽类小分子 PSMA 前列腺癌 Ⅰ期 AstraZeneca FPI-1434 Ac - 225 传统抗体 IGF-1R 子宫内膜癌、宫颈癌、卵巢癌、乳腺癌、头颈部肿瘤、黑色素瘤及皮肤肿瘤 Ⅰ期 AstraZeneca FPI-2068 Ac - 225 工程化抗体 / 蛋白 EGFR/cMET 头颈部肿瘤、非小细胞肺癌、结直肠癌、胰腺癌 Ⅰ期 AstraZeneca FPI-2265 Ac - 225 非肽类小分子 PSMA 前列腺癌 Ⅱ期 Bayer BAY3546828 Ac - 225 传统抗体 PSMA 前列腺癌 Ⅰ期 Bayer BAY3563254 Ac - 225 非肽类小分子 PSMA 前列腺癌 Ⅰ期 Bivision JH020002（JH02）Lu-177 Lu - 177 肽类 PSMA 前列腺癌 Ⅰ期 Blue Earth Therapeutics 177Lu-rhPSMA-10.1 Lu - 177 非肽类小分子 PSMA 前列腺癌 Ⅰ期 Bristol Myers Squibb RYZ801 Ac - 225 肽类 GPC3 肝癌 Ⅰ期 Bristol Myers Squibb RYZ101 Ac - 225 肽类 SSTR2 胃肠胰神经内分泌肿瘤、肺神经内分泌肿瘤、乳腺癌 Ⅲ期 Cancer Targeted Technology CTT1403 Lu - 177 非肽类小分子 PSMA 前列腺癌 Ⅰ期 CellBion 177Lu-PSMA-DGUL Lu - 177 非肽类小分子 PSMA 前列腺癌 Ⅱ期 Clarity 67Cu-SAR-bisPSMA Cu - 67 非肽类小分子 PSMA 前列腺癌 Ⅱ期 Clarity 67Cu-SAR-Bombesin Cu - 67 肽类 GRPR 前列腺癌 Ⅰ期 Clarity 67Cu-SARTATE Cu - 67 肽类 SSTR2 神经母细胞瘤 Ⅰ期 Convergent Therapeutics CONV01-α Ac - 225 传统抗体 PSMA 前列腺癌 Ⅱ期 Curium 177Lu-PSMA I&T Lu - 177 非肽类小分子 PSMA 前列腺癌 Ⅲ期 Eli Lilly PNT2001 Ac - 225 非肽类小分子 PSMA 前列腺癌 Ⅰ期 Eli Lilly PNT6555 Lu - 177 肽类 FAP 胰腺癌、肉瘤、食管癌、结直肠癌、黑色素瘤、头颈部肿瘤、胆管癌 Ⅰ期 FutureChem 177Lu-FC705（Ludotadipep） Lu - 177 小分子 PSMA 前列腺癌 Ⅱ期 GlyTherix 177Lu-Miltuximab Lu - 177 传统抗体 GPC-1 前列腺癌、膀胱癌 Ⅰ期 HengRui HRS-4357 未披露 未披露 PSMA 前列腺癌 Ⅱ期 ITM ITM-11 Lu - 177 肽类 SSTR2 胃肠胰神经内分泌肿瘤 Ⅲ期 ITM ITM-23 Tb - 161 非肽类小分子 PSMA 前列腺癌 Ⅰ期 ITM ITM-63 Tb - 161 肽类 SSTR2 胃肠胰神经内分泌肿瘤 Ⅰ期 ITM ITM-31 Lu - 177 工程化抗体 / 蛋白 CAXII 胶质母细胞瘤 Ⅰ期 ITM ITM-91 Lu - 177 肽类 CAIX 肾癌、胰腺癌、结直肠癌 Ⅰ期 J&J JNJ-69086420 Ac - 225 传统抗体 hK2 前列腺癌 Ⅰ期 Lantheus PNT2002 Lu - 177 非肽类小分子 PSMA 前列腺癌 Ⅲ期 Lantheus PNT2003 Lu - 177 肽类 SSTR2 胃肠胰神经内分泌肿瘤 Ⅲ期（已提交上市申请） Modulation MTI-201 Ac - 225 未披露 MC1R 黑色素瘤及皮肤肿瘤 Ⅰ期 Molecular Targeting Technologies 177Lu-EBTATE Lu - 177 肽类 SSTR2 胃肠胰神经内分泌肿瘤、肺神经内分泌肿瘤、甲状腺癌、头颈部肿瘤 Ⅱ期 Monopar MNPR-101-Lu Lu - 177 传统抗体 uPAR 膀胱癌、乳腺癌、肺神经内分泌肿瘤、非小细胞肺癌、结直肠癌、卵巢癌、胰腺癌 Ⅰ期 Novartis Pluvicto Lu - 177 非肽类小分子 PSMA 前列腺癌 已上市 Novartis Lutathera Lu - 177 肽类 SSTR2 胃肠胰神经内分泌肿瘤 已上市 Novartis AAA817（Ac-PSMA-617） Ac - 225 非肽类小分子 PSMA 前列腺癌 Ⅱ期 Novartis AAA603（177Lu-NeoB） Lu - 177 肽类 GRPR 乳腺癌、胶质母细胞瘤 Ⅱ期 Novartis FXX489（Lu-NNS309） Lu - 177 未披露 未披露 胰腺癌、非小细胞肺癌、乳腺癌、结直肠癌 Ⅰ期 Novartis AAA614（Lu-FAP-2286） Lu - 177 肽类 FAP 非小细胞肺癌、胰腺癌、乳腺癌 Ⅰ期 Novartis GIZ943（Lu-EVS-459） Lu - 177 未披露 FRα 卵巢癌、非小细胞肺癌 Ⅰ期 Novartis AAA802（225Ac-PSMA-R2） Ac - 225 非肽类小分子 PSMA 前列腺癌 Ⅱ期 Orano Med AlphaMedix Pb - 212 肽类 SSTR2 胃肠胰神经内分泌肿瘤 Ⅱ期 Orano Med 212Pb-GRPR Pb - 212 肽类 GRPR 前列腺癌、乳腺癌 Ⅰ期 PentixaPharm PentixaTher PT-002（Lu-177） Lu - 177 肽类 CXCR4 白血病 Ⅰ期 PentixaPharm PentixaTher PT-002（Y-90） 钇 - 90 肽类 CXCR4 淋巴瘤、多发性骨髓瘤 Ⅰ期 Perspective Therapeutics 212pb-VMT-α-NET Pb - 212 肽类 SSTR2 胃肠胰神经内分泌肿瘤 Ⅰ期 Perspective Therapeutics VMT01 Pb - 212 肽类 MC1R 黑色素瘤及皮肤肿瘤 Ⅰ期 Philogen OncoFAP Lu - 177 非肽类小分子 FAP FAP + 实体瘤 Ⅰ期 Precirix CAM-H2 I - 131 工程化抗体 / 蛋白 HER2 乳腺癌、胃癌、胃食管结合部癌 Ⅰ期 Radiopharm Therapeutics RAD204 Lu - 177 工程化抗体 / 蛋白 PD-L1 非小细胞肺癌 Ⅰ期 Ratio Therapeutics N/A Ac - 225 非肽类小分子 FAP 肉瘤 Ⅰ期 Sinotau XTR008（177Lu Oxodotreotide） Lu - 177 肽类 SSTR2 除 G1/G2 级胃肠胰神经内分泌肿瘤外的神经内分泌肿瘤 Ⅱ期 Sinotau XTR010 未披露 未披露 未披露 前列腺癌 未披露 Sinotau XTR017 / XT-117 Lu-177 Lu - 177 未披露 FAP 未指定 Ⅰ期 Telix TLX591 Lu - 177 传统抗体 PSMA 前列腺癌 Ⅲ期 Telix TLX250 Lu - 177 传统抗体 CAIX 肾癌 Ⅱ期 Telix TLX101 I - 131 非肽类小分子 LAT-1 胶质母细胞瘤 Ⅱ期 Telix TLX592 Ac - 225 传统抗体 PSMA 前列腺癌 Ⅰ期 Telix TLX66 Y- 90 传统抗体 CD66 骨髓清髓 Ⅱ期 Y-mAbs GD2-SADA Lu - 177 工程化抗体 / 蛋白 GD2 肺神经内分泌肿瘤、黑色素瘤及皮肤肿瘤、肉瘤、神经母细胞瘤 Ⅰ期 Y-mAbs CD38-SADA Lu - 177 工程化抗体 / 蛋白 CD38 非霍奇金淋巴瘤 Ⅰ期

The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing awareness of radioligand therapies, the increasing number of radioligand therapies that are under clinical trials including Novartis (177Lu-PSMA-617, 225Ac. 放射性配体疗法市场预计将在未来几年显著增长。这是由于被诊断患有癌症的患者数量不断增加，放射性配体疗法的认知度提高，以及越来越多的放射性配体疗法正在进行临床试验，包括诺华公司的177Lu-PSMA-617和225Ac等。‑ ‑PSMA 前列腺特异性膜抗原‑ ‑617, 177Lu-NNS309, 177Lu-NeoB, AAA614, and ESP359), Curium Pharma (177Lu-PSMA-I&T), Lantheus and Eli Lilly and Company (Lu-PNT2002 and LNTH-1095), Fusion Pharmaceuticals and AstraZeneca (FPI-2265), Clarity Pharmaceuticals (67CU SAR-BBN and 64Cu-SAR-BBN), and others. 617、177Lu-NNS309、177Lu-NeoB、AAA614 和 ESP359），Curium Pharma（177Lu-PSMA-I&T），Lantheus 和 Eli Lilly and Company（Lu-PNT2002 和 LNTH-1095），Fusion Pharmaceuticals 和 AstraZeneca（FPI-2265），Clarity Pharmaceuticals（67CU SAR-BBN 和 64Cu-SAR-BBN），以及其他公司。LAS VEGAS 拉斯维加斯, ，March 12, 2026 2026年3月12日/PRNewswire/ -- DelveInsight's Radioligand Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Breast cancer, Extensive-stage small cell lung cancer (ES-SCLC), Gastroenteropancreatic neuroendocrine tumors (GEP-NETs), Follicular Lymphoma, Glioblastoma multiforme, and others. /PRNewswire/ -- DelveInsight的放射配体疗法市场规模、目标人群、竞争格局及市场预测报告包含对当前治疗实践、可治疗患者群体的全面理解，其中包括乳腺癌、广泛期小细胞肺癌（ES-SCLC）、胃肠胰神经内分泌肿瘤（GEP-NETs）、滤泡性淋巴瘤、多形性胶质母细胞瘤等主要适应症。The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging Radioligand Therapies, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).. 所选适应症基于已批准的疗法和正在进行的研发管线活动。报告还提供了新兴放射配体疗法的见解、各疗法的市场份额，以及2020年至2034年当前和预测的市场规模，细分至主要市场（美国、欧盟四国、英国和日本）。Key Takeaways from the Radioligand Therapies Market Report 放射性配体疗法市场报告的关键要点The total market size of radioligand therapies in the leading markets is expected to surge significantly by 2034. 预计到2034年，主要市场中的放射配体疗法的总市场规模将大幅增长。In 2024, the United States holds the largest share of the radioligand therapies market among the 7MM. 2024年，在七大市场中，美国拥有放射配体疗法市场最大的份额。The report provides the total potential number of patients in the indications, such as 该报告提供了适应症中患者的总潜在数量，例如Breast cancer, Extensive-stage small cell lung cancer (ES-SCLC), Gastroenteropancreatic neuroendocrine tumors (GEP-NETs), Follicular Lymphoma, Glioblastoma multiforme, and others 乳腺癌、广泛期小细胞肺癌 (ES-SCLC)、胃肠胰神经内分泌肿瘤 (GEP-NETs)、滤泡性淋巴瘤、多形性胶质母细胞瘤等. 。In 2024, the 7MM had approximately 2024年，7MM大约有240,000 240,000prevalent cases of metastatic prostate cancer. 转移性前列腺癌的普遍病例。Leading radioligand therapies companies, such as 领先的放射配体治疗公司，如Novartis, Curium Pharma, Lantheus, Eli Lilly and Company, Fusion Pharmaceuticals, AstraZeneca, Clarity Pharmaceuticals, Bayer, ITM Isotope Technologies, ARTBIO, Convergent Therapeutics, Perspective Therapeutics, PRECIRIX, Ariceum Therapeutic, Nuclidium, 诺华、Curium制药、Lantheus、礼来公司、Fusion制药、阿斯利康、Clarity制药、拜耳、ITM同位素技术、ARTBIO、Convergent治疗学、Perspective治疗学、PRECIRIX、Ariceum治疗学、Nuclidiumand others, are developing novel radioligand therapies that can be available in the radioligand therapies market in the coming years. 和其他公司正在开发新型放射配体疗法，这类疗法可能在未来几年内投放到放射配体疗法市场。Some of the key radioligand therapies in clinical trials include 一些处于临床试验阶段的关键放射配体疗法包括177Lu-PSMA-617, 225Ac 177Lu-PSMA-617，225Ac‑ ‑PSMA 前列腺特异性膜抗原‑ ‑617, 177Lu-NNS309, 177Lu-NeoB, AAA614, ESP359, 177Lu-PSMA-I&T, Lu-PNT2002, LNTH-1095, FPI-2265, 67CU SAR-BBN, 64Cu-SAR-BBN, 225Ac-PSMA-Trillium, 225Ac-Pelgifatamab, 225Ac-GPC3, ITM-11, 212Pb-NG001, CONV01-α, VMT-α-NET, VMT01, PSV359, CAM-FAP-Ac-225, 225Ac-SSO110, ATT001, NU101, NU201, 617, 177Lu-NNS309, 177Lu-NeoB, AAA614, ESP359, 177Lu-PSMA-I&T, Lu-PNT2002, LNTH-1095, FPI-2265, 67CU SAR-BBN, 64Cu-SAR-BBN, 225Ac-PSMA-Trillium, 225Ac-Pelgifatamab, 225Ac-GPC3, ITM-11, 212Pb-NG001, CONV01-α, VMT-α-NET, VMT01, PSV359, CAM-FAP-Ac-225, 225Ac-SSO110, ATT001, NU101, NU201,and others. 和其他人。Discover how big is the radiopharmaceutical or radioligand therapy market @ 发现放射性药物或放射性配体治疗市场的规模有多大 @https://www.delveinsight.com/sample-request/radioligand-therapies-market-forecast https://www.delveinsight.com/sample-request/radioligand-therapies-market-forecastKey Factors Driving the Radioligand Therapies Market 推动放射配体疗法市场发展的关键因素Rising Global Cancer Burden: 全球癌症负担的增加：The increasing prevalence of cancers such as prostate cancer and neuroendocrine tumors (NETs) is a major factor driving demand for radioligand therapies. These therapies are particularly effective in treating cancers that are difficult to manage with conventional treatments like chemotherapy or external radiation.. 癌症（如前列腺癌和神经内分泌肿瘤 (NETs)）发病率的不断上升是推动放射配体疗法需求增长的主要因素。这些疗法在治疗难以通过传统方法（如化疗或外部放疗）控制的癌症时特别有效。Growing Demand for Targeted and Precision Oncology: 对靶向和精准肿瘤学的需求不断增长：Radioligand therapies deliver radioactive isotopes directly to tumor cells via specific ligands, enabling highly targeted destruction of cancer cells while minimizing damage to healthy tissue. 放射性配体疗法通过特定的配体将放射性同位素直接递送到肿瘤细胞，从而实现对癌细胞的高度靶向杀伤，同时最大限度地减少对健康组织的损害。Potential of 177Lu-PNT2002 for Chemotherapy-Naïve mCRPC Patients: 177Lu-PNT2002在化疗初治mCRPC患者中的潜力：177Lu-PNT2002, a late-stage PSMA-targeted radiotherapeutic candidate, is well-tolerated and holds significant potential in meeting the needs of chemotherapy-naïve mCRPC patients. 177Lu-PNT2002 是一种处于后期阶段的靶向 PSMA 的放射治疗候选药物，具有良好的耐受性，并在满足未接受过化疗的 mCRPC 患者需求方面展现出显著潜力。Rising Radioligand Therapies Clinical Trial Activities: 放射配体疗法临床试验活动的增加： The expected launch of radioligand therapies market are expected to change in the coming years due to the launch of emerging therapies such as 预计放射性配体疗法市场将在未来几年因新兴疗法（如某些疗法）的推出而发生变化，Novartis 诺华(177Lu-PSMA-617, 225Ac‑PSMA‑617, 177Lu-NNS309, 177Lu-NeoB, AAA614, and ESP359), (177Lu-PSMA-617、225Ac‑PSMA‑617、177Lu-NNS309、177Lu-NeoB、AAA614 和 ESP359),Curium Pharma 锔医药公司(177Lu-PSMA-I&T), （177Lu-PSMA-I&T），Lantheus and Eli Lilly and Company 兰索斯和礼来公司(Lu-PNT2002 and LNTH-1095), （Lu-PNT2002 和 LNTH-1095），Fusion Pharmaceuticals and AstraZeneca Fusion制药公司和阿斯利康(FPI-2265), （FPI-2265），Clarity Pharmaceuticals 清晰制药公司(67CU SAR-BBN and 64Cu-SAR-BBN), (67CU SAR-BBN 和 64Cu-SAR-BBN),Bayer 拜耳(225Ac-PSMA-Trillium, 225Ac-Pelgifatamab, and 225Ac-GPC3), （225Ac-PSMA-Trillium、225Ac-Pelgifatamab 和 225Ac-GPC3），ITM Isotope Technologies ITM同位素技术(ITM-11), (ITM-11)，ARTBIO 艺术生物(212Pb-NG001), (212Pb-NG001),Convergent Therapeutics 收敛治疗学(CONV01-α), （CONV01-α），Perspective Therapeutics 景观治疗学(VMT-α-NET, VMT01, and PSV359), （VMT-α-NET、VMT01 和 PSV359），PRECIRIX PRECIRIX(CAM-FAP-Ac-225), (CAM-FAP-Ac-225)，Ariceum Therapeutics 阿里瑟姆治疗公司(225Ac-SSO110 and ATT001), (225Ac-SSO110 和 ATT001),Nuclidium 核素(NU101 and NU201), and others. （NU101 和 NU201），以及其他。According to Sadaf Javed, Manager of Forecasting and Analytics at DelveInsight, the pharmaceutical industry is becoming more interested in targeted radiation therapy as a novel, promising cancer treatment option as a result of the LUTATHERA success story. 据德瓦尔洞察公司预测与分析经理萨达夫·贾韦德称，由于LUTATHERA的成功故事，制药行业对靶向放射治疗作为一种新颖且有前景的癌症治疗选择越来越感兴趣。Radioligand Therapies Market Analysis 放射性配体治疗市场分析Radioligand therapy is increasingly recognized as a promising cancer treatment approach. It is mainly used for patients with metastatic neuroendocrine tumors and those with prostate cancer who no longer respond to standard chemotherapy or radiotherapy. 放射性配体疗法正日益被视为一种有前途的癌症治疗方法。它主要用于转移性神经内分泌肿瘤患者以及那些不再对标准化疗或放疗产生反应的前列腺癌患者。This targeted therapy delivers radioactive agents directly to cancer cells, helping to prolong survival while improving patients' quality of life by reducing harm to surrounding healthy tissues. Several radioligand therapies, including 这种靶向治疗直接将放射性药物递送到癌细胞，有助于延长生存期，同时通过减少对周围健康组织的伤害来改善患者的生活质量。几种放射配体疗法，包括LUTATHERA, PLUVICTO, XOFIGO, and ZEVALIN LUTATHERA、PLUVICTO、XOFIGO 和 ZEVALIN, have already received approval from the US FDA. ，已经获得美国FDA的批准。Among them, LUTATHERA was the first radioligand therapy approved for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults and has recently gained approval for use in pediatric patients as well. 其中，LUTATHERA 是首个获批用于治疗成人胃肠胰神经内分泌肿瘤 (GEP-NETs) 的放射配体疗法，并且最近也获得了用于儿科患者的批准。The TheAmerican Society of Clinical Oncology (ASCO) 美国临床肿瘤学会 (ASCO)has also released a rapid guideline update regarding radiotracers used in PSMA PET imaging to support the selection of patients with mCRPC who may benefit from 还发布了关于PSMA PET成像中使用的放射性示踪剂的快速指南更新，以支持选择可能受益的mCRPC患者lutetium-177–labeled PSMA-617 radioligand therapy 镥-177标记的PSMA-617放射配体治疗. Expanding on the original 2014 guideline and its 2022 revision, the update now recommends three radiotracers, including the newly approved flotufolastat F-18, to evaluate patient eligibility. 在2014年原始指南及其2022年修订版的基础上，此次更新现在推荐使用三种放射性示踪剂，包括新批准的氟托福拉stat F-18，以评估患者的资格。In addition, the 此外，EANM/SNMMI 欧洲核医学协会/美国核医学与分子影像学会 procedural guidelines assist nuclear medicine specialists in identifying suitable candidates for 177Lu-PSMA radioligand therapy, conducting the treatment in line with best practices, and effectively managing potential adverse effects. 程序指南协助核医学专家确定适合进行177Lu-PSMA放射配体治疗的候选人，按照最佳实践进行治疗，并有效管理潜在的不良反应。Meanwhile, 同时，ARTBIO 艺术生物is advancing a new generation of alpha radioligand therapies (ARTs). The company has relocated its European research laboratories to Oslo Science Park in Oslo, Norway, a move that provides enhanced laboratory infrastructure and access to specialized preclinical expertise in radiotherapeutics. 正在推进新一代的α放射配体疗法 (ART)。该公司已将其欧洲研究实验室迁至挪威奥斯陆的奥斯陆科技园，此举提供了更先进的实验室基础设施，并获得了放射治疗领域专业的临床前专业知识。This transition is expected to accelerate the development of ARTBIO's ART pipeline and strengthen its radiation-enabled research and development capabilities. 这一转变预计将加速ARTBIO的ART管道的开发，并增强其辐射研究和开发能力。Learn more about next-generation radiopharmaceutical therapies @ 了解有关下一代放射性药物疗法的更多信息 @Radioligand Therapies Analysis 放射性配体治疗分析Radioligand Therapies Competitive Landscape 放射性配体治疗的竞争格局Some of the radioligand therapies under development include 一些正在开发的放射性配体疗法包括Novartis 诺华(177Lu-PSMA-617, 225Ac‑PSMA‑617, 177Lu-NNS309, 177Lu-NeoB, AAA614, and ESP359), (177Lu-PSMA-617、225Ac‑PSMA‑617、177Lu-NNS309、177Lu-NeoB、AAA614 和 ESP359),Curium Pharma 锔医药公司 (177Lu-PSMA-I&T), (177Lu-PSMA-I&T),Lantheus and Eli Lilly and Company 兰索斯和礼来公司(Lu-PNT2002 and LNTH-1095), （Lu-PNT2002 和 LNTH-1095），Fusion Pharmaceuticals and AstraZeneca 融合制药和阿斯利康 (FPI-2265), （FPI-2265），Clarity Pharmaceuticals 清晰制药公司(67CU SAR-BBN and 64Cu-SAR-BBN), (67CU SAR-BBN 和 64Cu-SAR-BBN),Bayer 拜耳(225Ac-PSMA-Trillium, 225Ac-Pelgifatamab, and 225Ac-GPC3), （225Ac-PSMA-Trillium、225Ac-Pelgifatamab 和 225Ac-GPC3），ITM Isotope Technologies ITM同位素技术(ITM-11), (ITM-11),ARTBIO 艺术生物(212Pb-NG001), (212Pb-NG001),Convergent Therapeutics 收敛治疗学(CONV01-α), （CONV01-α），Perspective Therapeutics 视角治疗学(VMT-α-NET, VMT01, and PSV359), （VMT-α-NET、VMT01 和 PSV359），PRECIRIX PRECIRIX(CAM-FAP-Ac-225), (CAM-FAP-Ac-225)，Ariceum Therapeutics 阿里瑟姆治疗公司(225Ac-SSO110 and ATT001), (225Ac-SSO110 和 ATT001),Nuclidium 核素(NU101 and NU201), and others. （NU101 和 NU201），以及其他。Curium Pharma's 177Lu-PSMA-I&T Curium Pharma的177Lu-PSMA-I&Tis designed to target the prostate-specific membrane antigen (PSMA), which is present in more than 85% of prostate cancer cells. Due to its high specificity for this antigen, the attached radioisotope selectively binds to and destroys PSMA-expressing tumor cells. The therapy is currently being evaluated in the Phase III ECLIPSE Phase III clinical trial (NCT05204927) for patients with mCRPC.. 旨在靶向前列腺特异性膜抗原（PSMA），这种抗原存在于超过85%的前列腺癌细胞中。由于其对该抗原的高特异性，附着的放射性同位素选择性结合并摧毁表达PSMA的肿瘤细胞。该疗法目前正在进行针对mCRPC患者的III期ECLIPSE临床试验（NCT05204927）评估。 Curium Pharma has been advancing its formulation of Lutetium Lu 177 Dotatate for several years, and in July 2024, the company announced the submission of a 505(b)(2) New Drug Application (NDA) for its Lutetium Lu 177 Dotatate Injection. Curium Pharma 多年来一直在推进其 Lutetium Lu 177 Dotatate 的配方，并于 2024 年 7 月宣布提交了其 Lutetium Lu 177 Dotatate 注射液的 505(b)(2) 新药申请 (NDA)。Eli Lilly and Company/Point BioPharma's PNT2002 礼来公司/Point BioPharma的PNT2002is another small-molecule PSMA-targeted radioligand therapy based on 177Lu for the treatment of mCRPC. It combines the PSMA-targeting ligand PSMA-I&T with the beta-emitting radioisotope no-carrier-added 177Lu. Lu‑PNT2002 is currently being studied in a Phase III clinical trial assessing its superiority over the standard of care in pre-chemotherapy mCRPC patients who have progressed after treatment with one androgen receptor pathway inhibitor. 是另一种基于177Lu的小分子PSMA靶向放射配体疗法，用于治疗mCRPC。它将PSMA靶向配体PSMA-I&T与无载体添加的β发射放射性同位素177Lu结合。Lu‑PNT2002目前正在一项III期临床试验中进行研究，评估其在先前接受过一种雄激素受体通路抑制剂治疗后进展的化疗前mCRPC患者中的优越性是否优于标准治疗。In December 2023, Eli Lilly and Company announced the completion of its acquisition of POINT Biopharma.. 2023年12月，礼来公司宣布完成对POINT Biopharma的收购。LNTH‑1095, also developed by Lantheus, is a PSMA-targeted small-molecule radioligand therapy intended for the treatment of mCRPC. The therapy links the PSMA-targeting ligand LNTH-1095 with a beta-emitting radioisotope and is currently being investigated in a Phase II trial for metastatic prostate cancer. LNTH‑1095也是由Lantheus开发的一种靶向PSMA的小分子放射配体疗法，旨在治疗mCRPC。该疗法将靶向PSMA的配体LNTH-1095与发射β射线的放射性同位素结合，目前正在进行一项针对转移性前列腺癌的II期临床试验。The company presented efficacy data for both Lu-PNT2002 and LNTH-1095 at the ESMO Oncology Congress 2024 held in September 2024.. 公司在2024年9月举行的2024年欧洲肿瘤内科学会（ESMO）大会上展示了Lu-PNT2002和LNTH-1095的有效性数据。Meanwhile, 同时，Fusion Pharmaceuticals 融合制药公司is advancing its lead candidate 正在推进其领先候选者FPI 浮动点数指数（FPI）‑ ‑2265 2265, which evaluates 225Ac-PSMA-I&T, a small molecule targeting PSMA expressed in prostate cancer cells. This alpha-emitting radiopharmaceutical is currently being studied in the TATCIST trial and the AlphaBreak trial. At present, BAMF Health is assessing FPI-2265 in collaboration with AstraZeneca and Fusion Pharmaceuticals.. ，评估225Ac-PSMA-I&T，这是一种靶向前列腺癌细胞中表达的PSMA的小分子。这种发射α粒子的放射性药物目前正在TATCIST试验和AlphaBreak试验中进行研究。目前，BAMF Health正与阿斯利康和Fusion Pharmaceuticals合作评估FPI-2265。177Lu-edotreotide 177Lu-edotreotideis ITM's proprietary synthetic targeted radiotherapeutic investigational drug being developed to treat gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The U.S. FDA has assigned a Prescription Drug User Fee Act (PDUFA) target decision date of August 28, 2026. 是ITM公司正在开发的用于治疗胃肠道胰腺神经内分泌肿瘤（GEP-NETs）的专有合成靶向放射治疗研究药物。美国FDA已指定《处方药使用者费用法案》（PDUFA）的目标决定日期为2026年8月28日。Convergent Therapeutics' CONV01-α (Ac-225 rosopatamab tetraxetan) 康维吉恩特治疗公司的CONV01-α（Ac-225罗索帕单抗四乙酸）is a proprietary, best-in-class radioantibody labeled with actinium-225 that has demonstrated encouraging efficacy and safety across several Phase 1/2 clinical studies in patients with prostate cancer. Patient enrollment for the CONVERGE-01 trial is currently in progress, while additional studies are being planned.. 是一种专有的、同类最佳的放射性抗体，标记有锕-225，在前列腺癌患者的多项1/2期临床研究中已显示出令人鼓舞的疗效和安全性。CONVERGE-01试验的患者招募目前正在进展中，同时正在计划更多的研究。The anticipated launch of these emerging therapies are poised to transform the radioligand therapies market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the radioligand therapies market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.. 这些新兴疗法的预期推出将在未来几年内改变放射性配体疗法市场的格局。随着这些尖端疗法不断成熟并获得监管批准，它们有望重塑放射性配体疗法市场，提供新的治疗标准，并为医疗创新和经济增长带来机遇。To know more about which companies are developing radioligand therapies, visit @ 要了解更多正在开发放射配体疗法的公司，请访问 @Radioligand Therapies Treatment 放射性配体治疗Recent Developments in the Radioligand Therapies Market 放射配体疗法市场的最新进展In 在March 2026, ITM Isotope Technologies Munich SE 2026年3月，慕尼黑ITM同位素技术公司presented post-hoc subgroup analyses from the Phase 3 ITM-11 COMPETE trial involving patients with Grade 1 or Grade 2 somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). 展示了来自3期ITM-11 COMPETE试验的事后亚组分析，涉及1级或2级生长抑素受体（SSTR）阳性的胃肠道胰腺神经内分泌肿瘤（GEP-NETs）患者。In 在March 2026, Lantheus Holdings, Inc. 2026年3月，兰特卢斯控股有限公司announced that the FDA had granted tentative approval to its Abbreviated New Drug Application (ANDA) for Lutetium Lu 177 Dotatate (PNT2003), a radioequivalent version of LUTATHERA (lutetium Lu 177 dotatate). 宣布FDA已对其镥177 Dotatate（PNT2003）的简略新药申请（ANDA）给予暂时批准，该药物是LUTATHERA（镥177 dotatate）的放射性等效版本。In 在January 2026, Zonsen PepLib Biotech Inc. 2026年1月，尊森PepLib生物科技公司announced a global licensing agreement with Novartis for an undisclosed peptide-based candidate in the radioligand therapy (RLT) space. As part of the deal, Novartis has secured exclusive worldwide rights and will oversee the asset's development and commercialization. 宣布与诺华达成了一项全球许可协议，涉及一款未公开的基于肽的放射配体治疗（RLT）候选药物。根据协议，诺华获得了该药物的全球独家权利，并将负责其开发和商业化。In 在January 2026, Swiss Rockets AG and Alloy Therapeutics, Inc. 2026年1月，瑞士火箭公司和合金治疗公司。entered into a Master Research Agreement (MRA) to initiate a multi-target partnership focused on the discovery and development of next-generation radioligand therapeutics (RLTs) for oncology. The collaboration will be carried out through Swiss Rockets' radiotherapeutics subsidiary, Torpedo Pharmaceuticals AG.. 签署了一份主研究协议 (MRA)，以启动一项多目标合作，专注于发现和开发用于肿瘤学的下一代放射配体治疗药物 (RLT)。该合作将通过瑞士火箭公司的放射治疗子公司 Torpedo Pharmaceuticals AG 进行。In 在January 2026, ARTBIO, Inc. 2026年1月，ARTBIO公司began dosing two U.S.-based patient cohorts in the ARTISAN Phase 1 trial of AB001, an alpha radioligand therapy designed to treat metastatic castration-resistant prostate cancer (mCRPC), enrolling patients with and without prior Lu177-PSMA targeted therapy exposure. 开始在ARTISAN第一阶段试验中对两个基于美国的患者队列进行AB001的剂量施用，这是一种旨在治疗转移性去势抵抗性前列腺癌（mCRPC）的α放射配体疗法，纳入了有和无先前Lu177-PSMA靶向治疗暴露的患者。In 在November 2025, ITM Isotope Technologies Munich SE 2025年11月，慕尼黑ITM同位素技术公司announced that the U.S. Food and Drug Administration had completed its filing review and accepted the company's New Drug Application (NDA) for n.c.a. 177Lu-edotreotide, also referred to as ITM-11. 宣布美国食品药品监督管理局已完成其档案审查，并接受了该公司关于n.c.a. 177Lu-edotreotide（也称为ITM-11）的新药申请（NDA）。What are Radioligand Therapies? 什么是放射配体疗法？Radioligand therapies (RLTs) are a class of targeted cancer treatments that combine a radioactive isotope with a ligand, a molecule designed to specifically bind to receptors or proteins that are highly expressed on tumor cells. Once administered, the ligand guides the radioactive payload directly to cancer cells, allowing the radiation to destroy malignant tissue while minimizing damage to surrounding healthy cells. 放射性配体疗法（RLTs）是一类靶向癌症治疗药物，它将放射性同位素与一种配体结合，这种配体是一种专门设计用于与在肿瘤细胞上高表达的受体或蛋白质特异性结合的分子。一旦施用，配体会引导放射性物质直接到达癌细胞，使辐射能够摧毁恶性组织，同时尽量减少对周围健康细胞的损害。This targeted approach improves therapeutic precision and reduces systemic toxicity compared to conventional radiation or chemotherapy. Radioligand therapies have shown significant promise in the treatment of several cancers, particularly prostate and neuroendocrine tumors. By integrating molecular targeting with radiation therapy, RLTs represent an emerging and rapidly evolving modality in precision oncology.. 这种有针对性的方法与传统的放疗或化疗相比，提高了治疗的精确性并减少了全身毒性。放射配体疗法在多种癌症的治疗中显示出显著的前景，特别是前列腺癌和神经内分泌肿瘤。通过将分子靶向与放射治疗相结合，放射配体疗法代表了精准肿瘤学中一种新兴且快速发展的治疗模式。Radioligand Therapies Epidemiology Segmentation 放射性配体疗法流行病学细分The radioligand therapies market report is a comprehensive and specialized analysis, offering in-depth epidemiological insights for the study period 2020–2034 across the leading markets. About 放射性配体治疗市场报告是一份全面且专业的分析，提供了2020-2034年研究期间主要市场的深入流行病学见解。关于80% 80%of SCLC cases were 65 or older, reflecting the advanced median age of diagnosis, 71 years. The radioligand therapies target patient pool is segmented into: 小细胞肺癌病例中65岁及以上的患者占多数，反映了诊断时的中位年龄为71岁。放射性配体疗法针对的患者群体分为：Total Cases of Selected Indications for Radioligand Therapies 所选放射性配体治疗适应症的总病例数Total Eligible Patient Pool for Radioligand Therapies in Selected Indications 特定适应症中放射配体疗法的总合格患者群体 Total Treated Cases in Selected Indications for Radioligand Therapies 选定适应症的放射配体治疗总病例数Radioligand Therapies Report Metrics 放射性配体疗法报告指标Details 详细信息Study Period 学习期2020–2034 2020–2034Radioligand Therapies Report Coverage 放射配体疗法报告覆盖范围7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] 七国集团 [美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本]Key Indications Covered in the Report 报告中涵盖的关键适应症Breast cancer, Extensive-stage small cell lung cancer (ES-SCLC), Gastroenteropancreatic neuroendocrine tumors (GEP-NETs), Follicular Lymphoma, Glioblastoma multiforme, and others 乳腺癌、广泛期小细胞肺癌 (ES-SCLC)、胃肠胰神经内分泌肿瘤 (GEP-NETs)、滤泡性淋巴瘤、多形性胶质母细胞瘤等Radioligand Therapies Target Patient Pool Segmentation 放射性配体疗法目标患者群体细分Total Cases of Selected Indications for Radioligand Therapies, Total Eligible Patient Pool for Radioligand Therapies in Selected Indications, and Total Treated Cases in Selected Indications for Radioligand Therapies 放射性配体疗法选定适应症的总病例数、选定适应症中放射性配体疗法的总合格患者池、以及选定适应症中放射性配体疗法的总治疗病例数Key Radioligand Therapies Companies 关键放射配体治疗公司Novartis, Curium Pharma, Lantheus, Eli Lilly and Company, Fusion Pharmaceuticals, AstraZeneca, Clarity Pharmaceuticals, Bayer, ITM Isotope Technologies, ARTBIO, Convergent Therapeutics, Perspective Therapeutics, PRECIRIX, Ariceum Therapeutic, Nuclidium, and others 诺华、Curium制药、Lantheus、礼来公司、Fusion制药、阿斯利康、Clarity制药、拜耳、ITM同位素技术、ARTBIO、Convergent治疗学、Perspective治疗学、PRECIRIX、Ariceum治疗学、Nuclidium等Key Radioligand Therapies 关键放射配体疗法177Lu-PSMA-617, 225Ac‑PSMA‑617, 177Lu-NNS309, 177Lu-NeoB, AAA614, ESP359, 177Lu-PSMA-I&T, Lu-PNT2002, LNTH-1095, FPI-2265, 67CU SAR-BBN, 64Cu-SAR-BBN, 225Ac-PSMA-Trillium, 225Ac-Pelgifatamab, 225Ac-GPC3, ITM-11, 212Pb-NG001, CONV01-α, VMT-α-NET, VMT01, PSV359, CAM-FAP-Ac-225, 225Ac-SSO110, ATT001, NU101, NU201, LUTATHERA, XOFIGO, PLUVICTO, ZEVALIN, and others. 177Lu-PSMA-617、225Ac‑PSMA‑617、177Lu-NNS309、177Lu-NeoB、AAA614、ESP359、177Lu-PSMA-I&T、Lu-PNT2002、LNTH-1095、FPI-2265、67CU SAR-BBN、64Cu-SAR-BBN、225Ac-PSMA-Trillium、225Ac-Pelgifatamab、225Ac-GPC3、ITM-11、212Pb-NG001、CONV01-α、VMT-α-NET、VMT01、PSV359、CAM-FAP-Ac-225、225Ac-SSO110、ATT001、NU101、NU201、LUTATHERA、XOFIGO、PLUVICTO、ZEVALIN等。Scope of the 范围Radioligand Therapies 放射性配体疗法Market Report 市场报告Radioligand Therapies Therapeutic Assessment: 放射性配体疗法治疗评估：Radioligand Therapies' current marketed and emerging therapies 放射性配体疗法的当前已上市和新兴疗法Radioligand Therapies 放射配体疗法Market Dynamics: 市场动态：Conjoint Analysis of Emerging Radioligand Therapies Drugs 新兴放射配体治疗药物的联合分析Competitive Intelligence Analysis: 竞争情报分析：SWOT analysis and Market entry strategies SWOT分析与市场进入策略Unmet Needs, KOL's views, Analyst's views, Radioligand Therapies Market Access and Reimbursement 未满足的需求、关键意见领袖的观点、分析师的观点、放射性配体疗法的市场准入和报销Discover upcoming radioligand therapies in oncology @ 发现肿瘤学中即将到来的放射配体疗法 @Radioligand Therapies Clinical Trials 放射性配体治疗临床试验Table of Contents 目录1 1Radioligand Therapies Market Key Insights 放射性配体疗法市场关键洞察2 2Radioligand Therapies Market Report Introduction 放射性配体治疗市场报告介绍3 3Key Highlights from Radioligand Therapies Market Report 放射配体疗法市场报告的关键亮点4 4Executive Summary of Radioligand Therapies 放射配体疗法的执行摘要5 5Key Events 关键事件6 6Epidemiology and Market Forecast Methodology 流行病学与市场预测方法论7 7Radioligand Therapies Market Overview at a Glance in the 7MM 七大市场放射性配体治疗市场概况一览 7.1 7.1Market Share (%) Distribution by Therapies in 2024 2024年各疗法市场份额（%）分布 7.2 7.2Market Share (%) Distribution by Therapies in 2034 2034年各疗法市场份额（%）分布 7.3 7.3Market Share (%) Distribution by Indication in 2024 2024年按适应症划分的市场份额（%）分布7.4 7.4Market Share (%) Distribution by Indication in 2034 2034年按适应症划分的市场份额（%）分布8 8Background and Overview 背景与概述8.1 8.1Introduction 介绍8.2 8.2Treatment 治疗9 9Target Patient Pool 目标患者群体9.1 9.1Key Findings 主要发现9.2 9.2Assumptions and Rationale: 7MM 假设与理由：7MM9.3 9.3Epidemiology Scenario in the 7MM 七大市场（7MM）的流行病学情景 9.3.1 9.3.1Total Cases in Selected Indications for Radioligand Therapies in the 7MM 7MM中放射配体疗法在选定适应症中的总病例数 9.3.2 9.3.2Total Eligible Patient Pool of Selected Indications for Radioligand Therapies in the 7MM 7MM中放射配体疗法选定适应症的总合格患者池9.3.3 9.3.3Total Treated Cases in Selected Indications for Radioligand Therapies in the 7MM 7MM中放射配体疗法在选定适应症中的总治疗病例数10 10Marketed Radioligand Therapies 上市的放射配体疗法10.1 10.1Key Competitors 主要竞争对手10.2 10.2 LUTATHERA (lutetium LU 177 dotatate): Novartis LUTATHERA（镥177 dotatate）：诺华10.2.1 10.2.1Product description 产品描述10.2.2 10.2.2 Regulatory milestones 监管里程碑10.2.3 10.2.3Other developmental activities 其他开发活动10.2.4 10.2.4 Safety and efficacy 安全性与有效性10.2.5 10.2.5 Product profile 产品概况10.3 10.3 PLUVICTO (lutetium lu-177 vipivotide tetraxetan): Novartis PLUVICTO（镥-177 维匹沃肽四乙酸）：诺华List to be continued in the report 报告中待续的列表11 11Emerging Radioligand Therapies 新兴放射配体疗法11.1 11.1Key Competitors 主要竞争对手11.2 11.2Lu-177-PSMA-I&T: Curium Pharma Lu-177-PSMA-I&T：Curium Pharma11.2.1 11.2.1Product description 产品描述11.2.2 11.2.2Other developmental activity 其他开发活动11.2.3 11.2.3Clinical developmental activities 临床发育活动11.2.3.1 11.2.3.1Clinical trial information 临床试验信息11.2.4 11.2.4Safety and efficacy 安全性与有效性11.3 11.3Lu-PNT2002: Lantheus and Eli Lilly and Company/Point BioPharma Lu-PNT2002：Lantheus 和 Eli Lilly and Company/Point BioPharma11.4 11.4FPI-2265: Fusion/Astrazeneca FPI-2265：Fusion/阿斯利康List to be continued in the report 报告中待续的列表12 12Radioligand Therapies Market: 7MM Analysis 放射性配体疗法市场：7MM分析12.1 12.1Key Findings 主要发现12.2 12.2Radioligand Therapies Market Outlook 放射性配体治疗市场展望12.3 12.3Conjoint Analysis 联合分析12.4 12.4Key Radioligand Therapies Market Forecast Assumptions 关键放射配体治疗市场预测假设12.5 12.5Radioligand Therapies Market Size by Indications in the 7MM 7MM中按适应症划分的放射性配体治疗市场大小12.6 12.6Radioligand Therapies Market Size by Therapies in the 7MM 七大市场（7MM）中按疗法划分的放射性配体治疗市场规模12.7 12.7United States Radioligand Therapies Market Size 美国放射配体疗法市场规模12.7.1 12.7.1Market Size by Indications in the US 美国各适应症市场规模12.7.2 12.7.2Market Size by Therapies in the US 美国按疗法划分的市场规模12.8 12.8EU4 and the UK Radioligand Therapies Market Size 欧盟四国和英国放射性配体治疗市场规模12.9 12.9Japan Radioligand Therapies Market Size 日本放射性配体疗法市场规模13 13Radioligand Therapies Market Unmet Needs 放射性配体疗法市场未满足的需求14 14Radioligand Therapies Market SWOT Analysis 放射性配体疗法市场SWOT分析15 15KOL Views on Radioligand Therapies 关键意见领袖对放射配体疗法的看法16 16Radioligand Therapies Market Access and Reimbursement 放射性配体疗法市场准入与报销17 17Bibliography 参考文献18 18Radioligand Therapies Market Report Methodology 放射性配体治疗市场报告方法论Related Reports 相关报告PSMA-targeted Therapy Market PSMA靶向治疗市场PSMA-targeted Therapy Market Size, Target Population, Competitive Landscape & Market Forecast PSMA靶向治疗市场规模、目标人群、竞争格局与市场预测– –2034 2034report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key PSMA-targeted therapy companies, including 报告深入介绍了该疾病的理解、历史和预测流行病学、各疗法的市场份额以及关键的PSMA靶向治疗公司，包括Lantheus, Telix Pharmaceuticals, Novartis 兰泰乌斯、特利克斯制药、诺华, and others. ，以及其他。Prostate Cancer Market 前列腺癌市场Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 前列腺癌市场洞察、流行病学和市场预测 - 2034年report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key prostate cancer companies, including 报告深入介绍了该疾病、历史和预测的流行病学，以及市场趋势、市场驱动因素、市场障碍和关键的前列腺癌公司，包括Sanofi, AstraZeneca, Astellas Pharma, Bayer, Novartis, Curium, Merck, Orion, Janssen Pharmaceutical, Pfizer, Exelixis, Ipsen Pharma, Takeda, AB Science, Lantheus, Eli Lilly, POINT Biopharma, Telix Pharmaceuticals, Tavanta Therapeutics, Jiangsu Hengrui Pharmaceuticals, Kangpu Biopharmaceuticals, Fusion Pharma, Merus, Bristol-Myers Squibb, Syntrix Pharmaceuticals, Promontory Therapeutics, Xencor, Taiho Pharmaceutical, Madison Vaccines, MacroGenics, Zenith Epigenetics, Modra Pharmaceuticals, Arvinas, Laekna Therapeutics, Blue Earth Therapeutics, Oncternal Therapeutics, Essa Pharma, Clarity Pharmaceuticals, BioNTech, DualityBio, Daiichi Sankyo, Fortis Therapeutics, ORIC Pharmaceuticals, Amgen,. 赛诺菲、阿斯利康、安斯泰来制药、拜耳、诺华、Curium、默克、奥立龙、杨森制药、辉瑞、Exelixis、益普生制药、武田、AB Science、Lantheus、礼来、POINT Biopharma、Telix Pharmaceuticals、Tavanta Therapeutics、江苏恒瑞医药、康朴生物医药、Fusion Pharma、Merus、百时美施贵宝、Syntrix Pharmaceuticals、Promontory Therapeutics、Xencor、大鹏制药、Madison Vaccines、MacroGenics、Zenith Epigenetics、Modra Pharmaceuticals、Arvinas、来凯医药、Blue Earth Therapeutics、Oncternal Therapeutics、Essa Pharma、Clarity Pharmaceuticals、BioNTech、DualityBio、第一三共、Fortis Therapeutics、ORIC Pharmaceuticals、安进。and others. 和其他人。Neuroendocrine Tumors 神经内分泌肿瘤Market 市场Neuroendocrine Tumors 神经内分泌肿瘤Market Insights, Epidemiology, and Market Forecast 市场洞察、流行病学和市场预测– –2034 2034report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key neuroendocrine tumors companies including 报告深入介绍了该疾病、历史和预测的流行病学，以及市场趋势、市场驱动因素、市场壁垒和主要神经内分泌肿瘤公司，包括Novartis, Merck, Pfizer, ITM Solucin GMBH, Camurus, Bristol Myers Squibb, Rayzebio, Exelixis, Ipsen, Takeda, Radiomedix, Orano Med, Perspective Therapeutics, Elicera Therapeutics, Chimerix, Enterome, Teclison 诺华、默克、辉瑞、ITM Solucin GMBH、Camurus、百时美施贵宝、Rayzebio、Exelixis、益普生、武田、Radiomedix、Orano Med、Perspective Therapeutics、Elicera Therapeutics、Chimerix、Enterome、Teclison, ，and others. 和其他人。Gastroenteropancreatic Neuroendocrine Tumors Market 胃肠胰神经内分泌肿瘤市场Gastroenteropancreatic Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast – 2034 胃肠胰神经内分泌肿瘤市场洞察、流行病学与市场预测——2034report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key GEP-NET companies including 报告提供了对疾病、历史和预测流行病学以及市场趋势、市场驱动因素、市场壁垒和主要GEP-NET公司的深入理解，包括Novartis, Ipsen Biopharmaceuticals, Pfizer, ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma Limited, Bristol-Myers Squibb, Eisai Limite, Experior S.L., Tarveda Therapeutics, Roche Pharma A, Exelixis, Merck Sharp & Dohme Corp, Recordati Inc, Eli Lilly and Company, Genentech, Inc., Aveo Oncology Pharmaceuticals, Radiomedix, Orano Med, PharmaMar, Bayer, Trio Medicines,. 诺华、益普生生物制药、辉瑞、慕尼黑ITM同位素技术、Camurus AB、和记黄埔医药有限公司、百时美施贵宝、卫材有限公司、Experior S.L.、Tarveda治疗学、罗氏制药、Exelixis、默克夏普和多姆公司、Recordati公司、礼来公司、基因泰克公司、Aveo肿瘤制药、Radiomedix、Orano Med、PharmaMar、拜耳、Trio医药。and others. 和其他人。About 关于DelveInsight 德莱夫洞察DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platformPharmDelve. 德尔维洞察（DelveInsight）是一家领先的商业咨询和市场研究公司，专注于生命科学领域。它通过提供全面的端到端解决方案来支持制药公司以提升其业绩。通过我们的订阅平台 PharmDelve，您可以轻松获取所有医疗保健和制药市场研究报告。. 。Contact Us 联系我们Shruti Thakur Shruti Thakur[emailprotected] 电子邮件地址+14699457679 +14699457679Logo: 标志：https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpgSOURCE DelveInsight Business Research, LLP 来源：DelveInsight商业研究公司21 21% %more press release views with 更多新闻稿浏览量与 Request a Demo 请求演示